In attendance

Members in attendance

• Director of Data and Analytics, Deputy Chief Data and Analytics Officer, NHS England (Chair)
• Director of Digital Operations and Innovation, Chelsea and Westminster Hospital NHS Foundation Trust
• Head of Information Governance, FDP, NHS England
• Assistant Head of Communications, Transformation Directorate, NHS England
• Director (Data and Analytics), Transformation, NHS England Medical Productivity Director, NHS England
• Director of Advanced Analysis, Data and Analytics, NHS England
• Deputy Managing Director, North of England Commissioning Support Unit
• Programme Management Director, IQVIA Director of Delivery, Palantir
• Assistant Director – Data Governance and Assurance, NHS England
• Principal Accountant, NHS England
• Finance Partnering Senior Lead, NHS England
• Deputy Director, Product Development and Implementation, NHS England
• National Medical Director for Secondary Care, Consultant Vascular and General Surgeon, NHS England
• Regional Director of Digital Transformation – East of England, NHS England
• Deputy Director, Demand and Delivery, NHS England Head of Communications and Engagement, NHS England
• Director of Data Management and Transformation, NHS England
• Director of Transformation and Quality Improvement, University Hospitals of Northamptonshire
• Senior Commercial Lead, NHS England
• Director of Delivery – National Cancer Programme, NHS England
• Chief Medical Officer, Kent Community Trust
• Regional Chief Operating Officer, Midlands, NHS England Director of UEC Delivery, NHS England
• Head of Procurement, Northumbria Healthcare NHS Foundation Trust
• Commercial Director, IQVIA
• Regional Director of Digital Transformation – Midlands, NHS England

Terms of Reference Members:

• Governance Secretariat Officer, Secretariat
• FDP Senior Governance Secretariat Officer, NHS England
• FDP Corporate and Governance Compliance Manager, NHS England
• Portfolio Director, NHS England
• Assistant Director FDP Programme Management Office, NHS England

In attendance (presenters/ad hoc):

• Virtual Wards Minimum Data Set (MDS) Delivery Lead, NHS England
• FDP Systems Engineer, NHS England Head of Delivery, NHS England
• FDP Centre of Excellence Lead, NHS England
• Programme Manager, NHS England

Apologies

• Joint Chief Digital Officer, Nottingham & Nottinghamshire ICS, Derby & Derbyshire ICS
• Director of Privacy, Transparency and Ethics, NHS England
• Chief Technology Officer, North of England Commissiong Support Unit
• Executive Director, Strategy Change and In Hospital Services, NHS Supply Chain, NHS England

1. Welcome and introductions

The Chair opened the meeting, welcomed the FDP Programme Board members, and noted apologies.

The Chair highlighted the ongoing work to establish operational excellence throughout the programme. Progress was noted on the transformation of data flows, alongside strengthened communications and engagement with both staff and the public. The Chair emphasised the focus on transforming and connecting care and improving patient pathways, all of which form a core part of delivering transformational excellence.

The minutes from the Programme Board meeting held on 1 September 2025 were reviewed and approved.

2. Declarations of interest

None.

3. Review of actions

The Board reviewed and noted the updated action log.

4. Decisions made

Decisions made by the Programme Board were noted by the Director of Data Transformation including those approved, rejected, and escalated.

Item for decision – Progress on implementing the Virtual Ward (VW) tool and flags risks and issues

The Board received an update on the Virtual Ward management tool and discussed ways to accelerate progress.

The Board agreed for a further update on the VW progress to the meeting in November 2025. Action: Schedule VW update to the November 2025 meeting.

5. FDP highlight report

The Board received an overview of the FDP Highlight Report to September 2025, noting progress against targets. Product development updates included the GA launch of Cancer 360 and the Shared Patient Treatment List, both positively received. Delivery of the System Coordination Centre (SCC) continues across six sites, with growing demand. KPIs remain on track, service management trends were improving, and interventions were being adjusted as needed.

The Board noted ongoing work to ratify Referral To Treatment (RTT) benefit numbers and that a forthcoming Centre of Excellence deep dive would evidence programme benefits.

The Chair highlighted the upcoming two-day FDP Build Event in October 2025, encouraging participation.

The Board noted the FDP Highlight Report.

6. FDP demand and delivery update

The Deputy Director for Demand and Delivery provided an update on the September 2025 FDP Demand and Delivery (D&D) activity.

It was noted that 94 Trusts were in delivery, with three additional Trusts expected to be onboarded shortly. Acute Trust delivery trajectory was reviewed, alongside any key themes identified. Work continued on ensuring thatthe process for signing Memorandum of Understanding (MoUs) documentation and delivery roll out was as efficient as possible.

The Chair noted the excellent progress being made. The recent Kent and Medway Trust workshop was highlighted as an example of innovative use of the FDP to address health inequalities, with interest expressed in sharing this work more widely. The Board discussed migration support and noted the work taking place to enhance capacity..

The Board received and noted the FDP Demand and Delivery update.

7. FDP product update

The Deputy Director of Product provided an update on national, local delivery and product progress.

Twenty products were currently under incubation phase, with key products progressing into General Availability (GA) and several at pilot stage. The incubation and pilot product status was reviewed, showing product locations and progression through the FDP roadmap. Positive exposure of AI-Assisted Discharge Summary (AADS) products was noted.

The Board members requested that future updates provide explanations for any acronyms in full to aid clarity to the reports. Action: PMO to include acronym sheet with next meeting pack

The Board discussed the productivity benefits and cost savings being unlocked as organisations adopt FDP products and more expensive existing applications and infrastructure are decommissioned.. It was confirmed that benefits continue to be tracked, including monetised savings.

In response to a query from a Board member, the Chair agreed that access to the benefits dashboard would be extended to all Regional Directors of Digital Transformation (RDDT). Action: Extend benefit dashboard access to all RDDTs a review methodology section.

The Board received and noted the Product Update.

8. NHS FDP Privacy Enhancing Technology (PET) Engine Configuration Deep Dive

The Board considered the outcome of a deep dive on PET. The update included detail on future capabilities and how these would support organisations.

The Board were updated on the purpose of the work, highlighting the maturity journey and the different phases from registration through to treatment. PET Data Protection Impact Assessments (DPIAs) would be released in September 2025, with an emphasis on what the process delivers and why it is important.

The configuration of PET and the distinction between PET and the PET engines were discussed.

The Chair confirmed the usefulness of the discussion and that the work strengthened the protections in place for identifiable data.

9. Centre of Excellence (CoE) Deep Dive

The CoE team joined the meeting for a deep dive session on the CoE outlining its purpose and key achievements to date. CoE was described as an enabler for the sustainability of the FDP, providing a platform that consolidates material on FDP and supports Trusts and national teams in building and utilising products.

Key achievements were summarised at national and local levels, with satisfaction rates reported at approximately 4.5 out of 5.

The meeting discussed how outcomes were tracked, noting the work in place to ensure that benefits were realised and triangulated and close oversight was ensured at every stage. Further development of a usage benefits workstream was being explored.

National highlights included developer enablement and the rollout of “FDP First.” The positive impact of intervention support provided by the CoE was noted, including increased user activity and improvements.

The Board received an overview of next steps and future outlook for the database, emphasising greater engagement, targeted interventions, enhanced collaboration, and additional capabilities.

The Chair noted that the CoE represents an important structure for the sustainability of FDP and stressed the need to maximise its value and ensure that it is widely advertised, which would encourage further uptake.

10. Any other business and close

The meeting concluded.

Date of next meeting: 4 November 2025
Completed by: Francis Ortega
Reviewed by: James Stanton
Confirmed by: Ayub Bhayat